×
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT

Uzbek court sentences 23, including Indian, over deaths linked to India-manufactured cough syrups

A court in Uzbekistan sentenced 23 people to prison terms on Monday over the deaths of 68 children linked to contaminated cough syrups produced by India's Marion Biotech, following a six-month-long trial.
Last Updated : 26 February 2024, 13:46 IST
Last Updated : 26 February 2024, 13:46 IST

Follow Us :

Comments

Tashkent: A court in Uzbekistan sentenced 23 people to prison terms on Monday over the deaths of 68 children linked to contaminated cough syrups produced by India's Marion Biotech, following a six-month-long trial.

The Central Asian nation had previously reported 65 deaths linked to the medicines, but last month the prosecutors at the Tashkent city court updated the death toll and said two more people had been charged during the hearings.

The defendants, including one Indian national, faced jail terms ranging from two to 20 years. They were found guilty of tax evasion, sale of substandard or counterfeit medicines, abuse of office, negligence, forgery, and bribery.

Singh Raghvendra Pratar, an executive director of Quramax Medical, a company that sold medicines produced by India’s Marion Biotech in Uzbekistan, was handed the longest – 20-year - prison term.

Former senior officials who were in charge of licensing imported medicines were also sentenced to lengthy terms.

The court decided that compensation amounting to $80,000 (1 billion Uzbek sums) would be paid to each of the families of 68 children who died from consumption of the syrup, as well as to four other children who became disabled.

Parents of eight other children affected by the drug will get from $16,000 to $40,000. The compensation money will be collected from seven of the convicts, the court’s decision said, according to the Supreme Court statement.

ADVERTISEMENT
Published 26 February 2024, 13:46 IST

Deccan Herald is on WhatsApp Channels | Join now for Breaking News & Editor's Picks

Follow us on :

Follow Us

ADVERTISEMENT
ADVERTISEMENT